Otros idiomas Veracyte, Inc.

Acciones

VCYT

US92337F1075

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 21:00:00 13/03/2026			Variación 5 días	Varia. 1 de enero.
32,13 ^USD	+3,88 %		-5,08 %	-23,68 %

06/03	Un directivo de Veracyte vende acciones por valor de 1.637.594 dólares, según una reciente notificación a la SEC	MT
06/03	Un directivo de Veracyte vende acciones por valor de 662.869 dólares, según una reciente notificación a la SEC	MT

Otros idiomas

06/03	Veracyte Insider Sold Shares Worth $1,637,594, According to a Recent SEC Filing
06/03	Veracyte Insider Sold Shares Worth $662,869, According to a Recent SEC Filing
04/03	Veracyte Insider Sold Shares Worth $485,429, According to a Recent SEC Filing
03/03	Veracyte : Raymond James 47th Annual Institutional Investors Conference
25/02	Veracyte Q4 Non-GAAP Earnings, Revenue Rise; Shares Gain After Hours
25/02	Veracyte : VCYT Q4 & FY 2025 Earnings Presentation
25/02	Veracyte : Webcast (veracyte fourth quarter and full year 2025 financial results webcast)
25/02	Earnings Flash (VCYT) Veracyte, Inc. Posts Q4 Adjusted EPS $0.53 per Share, vs. FactSet Est of $0.41
25/02	Veracyte: Q4 Earnings Snapshot
25/02	Earnings Flash (VCYT) Veracyte, Inc. Reports Q4 Revenue $140.6M, vs. FactSet Est of $135.4M
25/02	Veracyte, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
25/02	Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
25/02	Veracyte, Inc. Reiterates Earnings Guidance for the Year 2026
24/02	Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
19/02	Veracyte to Participate in Upcoming Investor Conferences
04/02	Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
11/01	Veracyte : Announces Preliminary Fourth Quarter and Full-Year 2025 Results
11/01	Veracyte, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025 and for the Year 2026
11/01	Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
29/12	Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
08/12	Veracyte Insider Sold Shares Worth $908,923, According to a Recent SEC Filing
06/11	Veracyte to Participate in Upcoming Investor Conferences
04/11	Veracyte: Q3 Earnings Snapshot
04/11	Veracyte : VCYT Q3 2025 Earnings Presentation
04/11	Veracyte : Webcast (veracyte third quarter 2025 financial results webcast)